Phosphoramidite Market Size & Share 2025 - 2034

Phosphoramidite Market Size

The global phosphoramidite market size was valued at USD 1.2 billion in 2024. The market is expected to grow from USD 1.3 billion in 2025 to USD 2.4 billion in 2034, at a CAGR of 7.2% during the forecast period. The rising demand for oligonucleotides and specific phosphoramidite for diagnostic, gene therapy and drug development are expected to spur business growth. For instance, as per Statista in November 2024, there were about 12,500 drugs in pre-clinical phase of research and development pipeline. Moreover, increasing advancements in biotechnology and pharmaceutical research also stimulate market growth.

According to Statista, the pharmaceutical industry is around USD 1.6 trillion and growing with a significant rate during the analysis period. Thus, the increasing demand for oligonucleotides, coupled with growing investments by major market players in the development of advanced genetic treatments, is leading to the launch of novel therapies and diagnostic methods. This, in turn, is expanding access to precise care for genetic disorders and driving the demand for phosphoramidite during the analysis period.
 

The phosphoramidite market is further strengthened by the increasing demand of synthetic biology, molecular biology research and whole genome sequencing resulting in increasing demand for DNA and RNA phosphoramidite for the synthesis of oligonucleotides. In addition, the advancement in gene editing technologies such as CRISPR-Cas9 has increased the demand for synthetic phosphoramidite, that contribute to market growth. Moreover, numerous governments and non-profit organizations are operating for genomic services and molecular biology research. These significant efforts will positively impact on the demand for phosphoramidite, thereby boosting the business revenue.
 

Moreover, the increasing prevalence of genetic disorders, infectious diseases and cancer has triggered the demand for targeted therapies that require the synthesis of oligonucleotides using phosphoramidite thereby further stimulating market growth. According to WHO, cancer is the leading cause of death and about 1 in 6 deaths are caused due to cancer. Additionally, the increasing demand for advanced technologies such as next generation sequencing (NGS) for rapid sequencing of genomes for early-stage detection also spur the demand for market growth.
 

Phosphoramidite are the chemical compounds utilized for the synthesis of oligonucleotides, that consists of short DNA or RNA molecules. These oligonucleotides play a crucial role in gene therapies, genetic research and molecular diagnostics. These are further utilized in applications such as gene editing, targeted drug discovery and next-generation sequencing. Phosphoramidite is essential for the development of specific oligonucleotide sequences according to individual genetic profiles for more accurate treatments.
 

Phosphoramidite Market Trends

• The market is stimulated by technological advancements, rising demand for customized phosphoramidite and growing preference for genomic research.
   
• Moreover, the rising adoption of next-generation sequencing (NGS) advanced platforms that rely on phosphoramidite for oligonucleotide synthesis is significantly boosting market demand. NGS diagnostics enable rapid and comprehensive sequencing of entire genomes within hours, facilitating the detection of genetic mutations and infectious diseases, ultimately leading to improved patient outcomes.
   
• In addition, gene editing technologies rely on phosphoramidite for the synthesis of oligonucleotides that target specific locations within the genome. This enables advanced therapeutic applications for the treatment of cancer and genetic disorders. The ability to precisely edit genes has opened new avenues for personalized medicine and the development of customized phosphoramidite, thereby contributing to market growth.
   
• An increasing trend of customized phosphoramidite is playing a crucial role in biotechnology for synthesis of specific oligonucleotides. For instance, TriLink BioTechnologies provides customized phosphoramidite that offer oligonucleotides with specific sequence and required modifications that are used in gene editing, RNA-based therapies and molecular diagnostics.
   
• Additionally, phosphoramidite are also used in polymerase chain reaction (PCR) and other diagnostic assays that help detect any kind of mutation or biomarkers related to diseases and disorders. As the focus shifts towards early detection and precision medicine the demand for high quality phosphoramidite has increased, that spurs market growth. 
   
• The rising healthcare expenditure globally increases the demand for phosphoramidite, government initiatives and private investors investing more in healthcare infrastructure and advancements resulting in accelerating the demand in research and clinical applications.
   
• Moreover, the integration of artificial intelligence (AI) and machine learning (ML) are helping to advance genetic research and drug discovery, stimulating market growth. AI can be used to analyze genetic data to potential drug targets and optimize gene therapies.
   
• Lastly, the key players operating in the market are continuously involved in research and development activities and invest heavily in the development of advanced options, thereby contributing to market growth.
   

Phosphoramidite Market Analysis

In 2021, the global market was valued at USD 1.01 billion. The following year, it saw a slight increase to USD 1.07 billion, and by 2023, the market further climbed to USD 1.14 billion. Based on type, the global market is divided into DNA phosphoramidite, RNA phosphoramidite and other types. The DNA phosphoramidite segment dominated the market in 2024 and was valued at USD 642.8 million.
 

• The increasing demand for oligonucleotide therapies and genetic research that require DNA phosphoramidite which are important in the process of synthesis for DNA and RNA sequencing, amplified market growth. As phosphoramidite is used for oligonucleotide synthesis, high quality phosphoramidite results in precise and scalable production of genetic materials, increasing their utilization in areas such as gene therapy and molecular diagnostics.
   
• Moreover, the presence of advanced synthesis technologies, along with improved purification methods and automation have helped production of more efficient and cost-effective DNA phosphoramidite, that contributes to increasing demand in the market.
   
• Additionally, the increasing outsourcing to contract development and manufacturing organizations by Pharma and biotech companies that rely on phosphoramidite chemistry for large-scale production, drives the market growth.
   
• Lastly, the increasing regulatory approvals for DNA and RNA therapies along with the product availability from suppliers globally stimulate the market growth for DNA phosphoramidite. The rising trend of personalized medicine with faster and accurate diagnosis mounts the demand for DNA phosphoramidite in the biopharmaceutical sector.

Learn more about the key segments shaping this market

Download Free PDF

Based on the application, the global phosphoramidite market is categorized into drug discovery and development, diagnostics, personalized medicine and other applications. In 2024, the drug discovery and development segment accounted for the largest share of 38.7% in global market.
 

• The increasing focus on advancement in new therapies for the treatment of various diseases stimulates the demand for phosphoramidite in drug discovery and development.
   
• The rising focus on drug discovery such as DNA and RNA therapies where crucial synthesis along with précised oligonucleotide are required, further advancing the therapeutic development.
   
• The rising prevalence of chronic diseases further stimulates the need for drug discovery and development. Moreover, early detection of diseases by utilization of advanced diagnostic methods such as PCR which require customized phosphoramidite further accelerates the market growth.
   
• The rising prevalence of infectious and genetic disorders is driving the demand for greater accuracy in diagnostic methods, thereby contributing to the growing demand for phosphoramidite.
   
• Additionally, advancements in screening methods are enhancing drug discovery by improving the development process and reducing both time and cost. These technological innovations are accelerating market demand for phosphoramidite in drug development applications.
   

Based on the end use, the global phosphoramidite market is categorized into pharmaceutical and biotechnology companies, academic and research institutes and other end users. The pharmaceutical and biotechnology companies segment dominated the market in 2024 and is anticipated to reach USD 1.3 billion by 2034 with a significant CAGR of 7.5% during the analysis period.
 

• Advancing oligonucleotide therapies with phosphoramidite plays a crucial role in biotechnology and pharmaceutical companies for drug discovery and development processes.
   
• In addition, the increasing focus on genetic therapies and RNA-based treatments has stimulated the demand for high-quality phosphoramidite, increasing the role of biotechnology and pharmaceutical sectors.
   
• The pharmaceutical and biotechnology companies invest heavily with collaboration and partnership with academic and research institutes for the development of novel therapies that target genetic disorders, cancer, and infectious diseases. For example, in March 2023, CPI, AstraZeneca, Novartis, and the University of Manchester, announced a collaboration to increase large-scale manufacture of oligonucleotides. Phosphoramidite is essential for synthesizing custom oligonucleotides that help in targeting various chronic and infectious disease, further contributing to the expansion of the market in this sector.
   
• The increasing demand for personalized medicine and the rising focus on genetic testing has further mentioned the role of biotechnology and pharmaceutical companies in driving innovations in drug development. They utilize advanced technologies and research programs for continuing the accelerated use of phosphoramidite, further contributing to the growth of the market segment.

The North America phosphoramidite market dominated the global market with a market share of 44.1% in 2024. The market is driven by the strong presence of biotech and pharmaceutical industries, coupled with the availability of advanced research and development ecosystems. The presence of advanced technologies such as CRISPR-Cas gene editing, synthetic biology, and high-throughput DNA/RNA synthesis, all of which require reliable phosphoramidite reagents also support market growth.
 

The U.S. market was valued at USD 405.7 million and USD 430.9 million in 2021 and 2022, respectively. The market size reached USD 487.9 million in 2024, growing from USD 458.2 million in 2023.
 

• The increasing demand for oligonucleotide-based therapies for molecular diagnosis and therapies are stimulating market growth. High investments in U.S. witnessed for genetic research and health advancements. For instance, according to NIH, the increase in funding for gene therapy research has increased due to promising results for treatment of many diseases contributing to the rising demand for phosphoramidite used in precision medicine applications.  
   
• Moreover, the increasing demand for high-quality reagents and solutions used in oligonucleotide synthesis for gene therapies and next-generation sequencing, drives the growth of the market.
   
• This market growth is driven by favorable government initiatives, increasing prevalence of targeted diseases treatment, the presence of key industry players and rising fundings, for the development of DNA and RNA based phosphoramidite in U.S. For example, In August 2022, the Department of Health and Human Services allocated funds for the support to advanced research focusing on structural birth defects, utilizing human translational and clinical methods (such as genomics, metabolomics, and proteomics).
   

Europe phosphoramidite market accounted for USD 331.7 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Europe has a strong and established healthcare industry, with a well-developed pharmaceutical and biotechnology sector, which is anticipated to spur market growth.
   
• Moreover, there is a significant investment in research and development across Europe, driven by both public and private sectors, to advance genomics, molecular diagnostics, and personalized medicine will boost the market in the Europe region.
   
• Also, the presence of key market players in the region reinforces Europe’s strength in the market. These companies are actively participating in innovation through the development of innovative solutions, thereby aiding market growth.
   

Germany dominates the European phosphoramidite market, showcasing strong growth potential.
 

• Germany leads the Europe market with high accessibility and advanced facilities. This further supports early diagnosis and gene therapy, contributing to the overall market growth.
   
• Moreover, the genomDE National Strategy for Genomic Medicine helps the healthcare system by introduction of genome sequencing in routine medical care that contributes to disease prevention, diagnosis, and treatment, especially for rare and oncological conditions.
   
• This initiative includes funding from the Federal Ministry of Health and collaboration with the EU's 1+ Million Genomes Initiative, aims to establish a nationwide platform for medical genome sequencing that contributes to the need for high-quality reagents such as phosphoramidite in genomic research and clinical applications.
   
• Lastly, companies such as Glen Research are investing in advancing product offerings that contribute to the growing need for customized phosphoramidite in both academic research and commercial applications, ensuring the supply of high-quality materials.
   

The Asia Pacific phosphoramidite market is anticipated to grow at the highest CAGR of 7.7% during the analysis timeframe.
 

• The rising prevalence of genetic disorders, cancers, and chronic infections across emerging economies such as India, China, and Southeast Asia, drives the growth of the market.
   
• Moreover, the expansion of CDMOs and CROs in APAC offering oligonucleotide synthesis and related services notably in India, China, and South Korea. Thus, the availability of cost-effective labor and infrastructure attract global pharma and biotech companies for outsourcing, that further contributes to market growth.
   

China phosphoramidite market is estimated to grow with a significant CAGR, in the Asia Pacific market.
 

• The increasing demand for precise medicine in genetic technologies is stimulating the market for phosphoramidite in China. Initiatives that improve prevention, diagnosis and treatment of diseases such as China’s Precision Medicine Initiative integrate genomic data and clinical practices, drives the market growth.
   
• Moreover, the Chinese government further allocates funding for the development of genetic medicine and synthetic biology, further increasing the demand for phosphoramidite.
   
• Companies such as Bioneer Corporation and Sigma-Aldrich are expanding production to surge in demand, with Bioneer’s facilities focuses on scaling up the synthesis of phosphoramidite for drug discovery.
   
• Lastly, the Chinese National Genomic Data Center (NGDC) that is established by Beijing Institute of Genomics is contributing to large scale genomic data collection advancing the demand for phosphoramidite.
   

Brazil leads the Latin American phosphoramidite market, exhibiting remarkable growth during the analysis period.
 

• The growing pharmaceutical and biotechnology industries are increasing the demand for phosphoramidite, that are important in genetic research and development of personalized medicines.
• Aligning with international trends the government has taken approaches to initiate expanding access to gene therapies.
   
• Brazil's National Health Surveillance Agency (ANVISA) is further overseeing pharmaceutical innovation, that ensures safety and efficacy of gene therapies.
   
• With the rapid development of biotechnology infrastructure and the growing partnerships between global suppliers and local players, Brazil's demand for phosphoramidite is expected to continue rising.
   

Saudi Arabia phosphoramidite market to experience substantial growth in the Middle East and Africa market in 2024.
 

• Saudi Arabia is undergoing development in healthcare transformation due to its Vision 2030 initiative, that mainly focuses on biotechnology and health innovation. The government initiatives play a crucial role, such as large-scale investments in the healthcare infrastructure resulting in rapid advancements in medical research, particularly in the field of genetic diagnostics and treatments.
   
• Saudi Arabia's King Abdulaziz City for Science and Technology (KACST) is stimulating genetic research projects and clinical applications, which further grows demand in market.
   
• In addition, global companies such as Thermo Fisher Scientific expand in Saudi Arabia by supplying essential materials used in genetic testing and oligonucleotide synthesis, thus supporting the growth of the market.
   
• Moreover, Saudi Arabia’s government provides various subsidies utilized for research and development, for universal healthcare system. High-cost treatments are often covered under government programs, helping patients reduce financial barriers.
   

Phosphoramidite Market Share

The top 6 players such as Thermo Fisher, Merck, Danaher, LGC Biosearch Technologies, Qiagen and Hongene Biotech account for approximately 60%-70% of the market share in 2024. These players focus on various strategies such as acquisition, investments, research and development activities and novel product launches to consolidate their market presence. For instance, in 2022, Merck KGaA invested in heavily research and development, ensuring commitment in innovation for nucleic acid isolation and purification. The companies are actively adopting a multi-pronged approaches to address the rising demand for market.
 

Moreover, key players are engaging in strategic initiatives such as collaboration, product launch, investment, and partnerships to strengthen their product portfolio. In September 2024, QIAGEN launched the QIAcuityDx Digital PCR System, which is expected to boost the demand for phosphoramidite as it contributes to precise molecular diagnostics and personalized medicine. As digital PCR and genomic medicine advances result in requirement for high-quality oligonucleotide synthesis. Companies are actively adopting multi-pronged approaches to address the rising demand for phosphoramidite. Moreover, the market is consolidated with few players operating in the market. Hence, leading players are constantly adopting key strategies for the growth of the market.
 

Phosphoramidite Market Companies

Prominent players operating in the phosphoramidite industry are as mentioned below:

• Bioneer
• Biosynth
• BOC Sciences
• ChemGenes
• Creative Biolabs
• Danaher
• Glen Research
• Hongene Biotech
• LGC Biosearch Technologies
• Lumiprobe
• PolyOrg
• Sigma-Aldrich (Merck KGaA)
• Qiagen
• Thermo Fisher Scientific
• TriLink Bio Technologies
   

Many leading players focus on product approval, advancements and collaboration to gain a competitive edge in the market. For instance, in March 2024, Primopus's Amideus brand mentioned its role for advancement of oligonucleotide therapies by providing affordable phosphoramidite. This focuses to aim challenges in oligonucleotide production, such as high costs and environmental concerns, by enhancing manufacturing facilities in Switzerland and India.
 

Merck offers high-purity phosphoramidite tailored for demanding applications in oligonucleotide synthesis, gene editing, and mRNA-based therapies. Their products are backed by stringent quality control, GMP-grade options, and scalable manufacturing to support both research and commercial needs.
 

With global supply chain capabilities and extensive technical support, Merck ensures reliable access and regulatory compliance for biopharma and diagnostic innovators. Their commitment to innovation also includes modified and specialty amidites for advanced nucleic acid designs.
 

Phosphoramidite Industry News

• In November 2024, Codexis presented their use of Enzyme Catalyzed Oligonucleotide (ECO) Synthesis platform to produce the siRNA drug. This was an important change in RNA therapy production that offered an eco-friendly method that reduced chemical waste and used better conditions as compared to traditional methods. Codexis also mentioned their specially engineered enzymes which are better than regular enzymes, that help in production of high-quality RNA therapies on a larger scale.
   
• In March 2024, TriLink BioTechnologies patented its CleanCap technology in China and Canada which strengthened its global intellectual property. In addition, this company and FUJIFILM Toyama Chemical came into an agreement for utilization of CleanCap M6 and other caps for the purpose of mRNA development, that resulted in the growing demand for high-quality RNA oligonucleotides. This grows the market for market as the product utilizes phosphoramidite in their synthesis.
   
• In May 2023, Twist Bioscience and CeGaT launched a product used to detect RNA fusions and conduct transcript for oncology research named as the Twist Alliance CeGaT RNA Fusion Panel. This panel, along with Twist's RNA Library Prep and CeGaT's diagnostic expertise, helps detect the of fusion genes in cancer, that require oligonucleotide synthesis with the utilization of phosphoramidite. This aims to broaden the diagnostic availability of the company.
   
• In March 2024, Oligo Factory announced a new manufacturing facility in Holliston, MA, that increased oligonucleotide synthesis capacity by 12 times to meet rising demand in the biotech and pharmaceutical sectors. This expansion with the help of investments by Research Corporation Technologies and BroadOak Capital Partners, helps to scale its production of custom oligonucleotides for gene therapies, diagnostics and research applications.
   

The phosphoramidite market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• DNA phosphoramidites
• RNA phosphoramidites
• Other types

Market, By Application

• Drug discovery and development
• Diagnostics
• Personalized medicine
• Other applications

Market, By End Use

• Pharmaceutical and biotechnology companies
• Academic and research institutes
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE